BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Ascletis Completes Dosing in U.S. Trial of ASC47 and Semaglutide for Obesity

The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day ...

July 15, 2025 | News

Amarna Therapeutics and NorthX Biologics Advance Nimvec™ AM510 Toward Clinical Trials for Type 1 Diabetes

Fast-Tracking Clinical Readiness: The agreement enables process and analytical development activities required to advance Nimvec™ AM510 for Type 1 ...

July 14, 2025 | News

Earendil Labs Completes First Cohort Dosing in Phase 1 Trial of Novel Anti-TL1A Antibody HXN-1001

Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibo...

July 11, 2025 | News

Medidata Expands Partnership with NHMRC Clinical Trials Centre to Accelerate Innovation in Australian Clinical Research

Continuing collaboration will utilize the capabilities of the Medidata Data Experience, fostering efficiency, fast-tracking research breakthroughs, and rai...

July 10, 2025 | News

SCG Cell Therapy Secures China NMPA IND Approval for First Cell Therapy Targeting Chronic Hepatitis B

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announ...

July 08, 2025 | News

InnoCare Pharma Receives IND Approval in China for Novel B7-H3 Targeted ADC ICP-B794

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the approval of the Inves...

July 07, 2025 | News

Akeso Doses First Patient in Phase Ia Trial of AK146D1, the World’s First Bispecific ADC Targeting Trop2 and Nectin4

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a...

July 04, 2025 | News

Ascletis Doses First Participants in U.S. Phase IIa Trial of Oral Small Molecule GLP-1 Agonist ASC30 for Obesity

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a ...

July 03, 2025 | News

Dizal Secures FDA Approval for ZEGFROVY, the First Targeted Oral Therapy for EGFR Exon20ins NSCLC

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins Approval follows the U....

July 03, 2025 | News

Taiwan Steps Into the Global Spotlight With a New Cancer Therapy

Traditional therapies often fall short in targeting these aggressive cancers with precision or safety. Can SOB100 improve drug delivery without the usual s...

July 02, 2025 | Report

The Importance of a Patient’s Mental Health During Clinical Trials

Most trial participants already have existing health issues. The added burden of trial participation can impact their emotional and psychological well-bein...

July 02, 2025 | Report

Klotho Neurosciences Advances KLTO-202 Gene Therapy Manufacturing for ALS Clinical Trials

Klotho Neurosciences, Inc. announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of K...

July 01, 2025 | News

Alpha Fusion and Curadh Forge Joint Venture to Advance Astatine-211 Radiopharmaceuticals Globally

Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture t...

July 01, 2025 | News

Innovent Biologics Secures NMPA Approval for World’s First Dual GCG/GLP-1 Receptor Agonist Mazdutide for Weight Management in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

June 30, 2025 | News

Stay Connected